Fpc Investment Advisory, Inc. Summit Therapeutics Inc. Transaction History
Fpc Investment Advisory, Inc.
- $137 Billion
- Q4 2024
A detailed history of Fpc Investment Advisory, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Fpc Investment Advisory, Inc. holds 1,946 shares of SMMT stock, worth $41,391. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,946
Previous 1,946
-0.0%
Holding current value
$41,391
Previous $36.8 Million
13.63%
% of portfolio
0.03%
Previous 0.03%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
230Shares Held
83.1MCall Options Held
1.63MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$520 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$248 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$168 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$139 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$119 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.28B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...